Literature DB >> 14597406

Inhibition of chemokine receptor function by membrane cholesterol oxidation.

Dzung H Nguyen1, Dennis D Taub.   

Abstract

Membrane cholesterol is required to maintain chemokine receptor conformation and function for CXCR4 and CCR5. We previously demonstrated that chemokines preferentially bind to receptors within lipid rafts, which are cholesterol- and sphingolipid-rich membrane microdomains. To further elucidate the role of cholesterol in chemokine receptor function, we examined the effects of membrane cholesterol oxidation by cholesterol oxidase (CO), which enzymatically converts cholesterol to 4-cholesten-3-one. Here, we demonstrate that CO treatment (0.25-2.0 U/ml) of human T cells inhibits CXCL12 (SDF-1alpha) and CCL4 (MIP-1beta) binding to cell surface CXCR4 and CCR5, respectively, resulting in the inhibition of chemokine-mediated intracellular calcium mobilization and chemotaxis. The effects were significantly enhanced by cotreatment with low-dose sphingomyelinase (SMase) (0.125 mU/ml), which produced little inhibitory effect by itself. CO and SMase treatment also inhibited HIV-1 infection through CXCR4, but not virus replication. Similar to the removal of membrane cholesterol, CO/SMase treatment induced conformation changes in the chemokine receptors as detected by differential loss in binding of epitope-specific monoclonal antibodies. We conclude that the native form of cholesterol with the hydroxyl group at C3 is critical to CXCR4 and CCR5 conformation and function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14597406     DOI: 10.1016/s0014-4827(03)00345-8

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  26 in total

1.  Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol.

Authors:  Ross M Potter; Kaleeckal G Harikumar; S Vincent Wu; Laurence J Miller
Journal:  J Lipid Res       Date:  2011-10-21       Impact factor: 5.922

Review 2.  Mechanisms regulating chemokine receptor activity.

Authors:  Laura D Bennett; James M Fox; Nathalie Signoret
Journal:  Immunology       Date:  2011-11       Impact factor: 7.397

3.  Membrane cholesterol depletion reduces downstream signaling activity of the adenosine A2A receptor.

Authors:  Claire McGraw; Lewen Yang; Ilya Levental; Edward Lyman; Anne Skaja Robinson
Journal:  Biochim Biophys Acta Biomembr       Date:  2019-01-08       Impact factor: 3.747

4.  Agonist-induced endocytosis of CC chemokine receptor 5 is clathrin dependent.

Authors:  Nathalie Signoret; Lindsay Hewlett; Silène Wavre; Annegret Pelchen-Matthews; Martin Oppermann; Mark Marsh
Journal:  Mol Biol Cell       Date:  2004-12-09       Impact factor: 4.138

5.  Production of Chemokine/Chemokine Receptor Complexes for Structural Biophysical Studies.

Authors:  Martin Gustavsson; Yi Zheng; Tracy M Handel
Journal:  Methods Enzymol       Date:  2015-12-14       Impact factor: 1.600

6.  Ceramide, a target for antiretroviral therapy.

Authors:  Catherine M Finnegan; Satinder S Rawat; Anu Puri; Ji Ming Wang; Francis W Ruscetti; Robert Blumenthal
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-15       Impact factor: 11.205

Review 7.  The Role of Platelet-Activating Factor in Chronic Inflammation, Immune Activation, and Comorbidities Associated with HIV Infection.

Authors:  Theodoros Kelesidis; Vasiliki Papakonstantinou; Paraskevi Detopoulou; Elizabeth Fragopoulou; Maria Chini; Marios C Lazanas; Smaragdi Antonopoulou
Journal:  AIDS Rev       Date:  2015 Oct-Dec       Impact factor: 2.500

Review 8.  The function of G-protein coupled receptors and membrane cholesterol: specific or general interaction?

Authors:  Yamuna Devi Paila; Amitabha Chattopadhyay
Journal:  Glycoconj J       Date:  2008-12-04       Impact factor: 2.916

9.  The Role of Lipids in Retrovirus Replication.

Authors:  Abdul A Waheed; Eric O Freed
Journal:  Viruses       Date:  2010-05-01       Impact factor: 5.048

10.  Antiretroviral effect of lovastatin on HIV-1-infected individuals without highly active antiretroviral therapy (The LIVE study): a phase-II randomized clinical trial.

Authors:  Carlos J Montoya; Fabian Jaimes; Edwin A Higuita; Sandra Convers-Páez; Santiago Estrada; Francisco Gutierrez; Pedro Amariles; Newar Giraldo; Cristina Peñaloza; Maria T Rugeles
Journal:  Trials       Date:  2009-06-18       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.